GeneHealth - Your precision medicine

Choroideremia

Disease Details

Family Health Simplified

Buy Membership

Description: Choroideremia is a rare, inherited disorder that causes progressive vision loss due to degeneration of the choroid, retina, and retinal pigment epithelium.
Type: Choroideremia is a type of inherited retinal dystrophy. Its genetic transmission is X-linked recessive.
Signs And Symptoms: Choroideremia is a rare, inherited disorder that leads to progressive vision loss due to the degeneration of the choroid, retina, and retinal pigment epithelium. The signs and symptoms include:

- **Night blindness**: Often the first symptom, typically starting in childhood.
- **Peripheral vision loss**: Gradual constriction of the visual field, leading to "tunnel vision."
- **Central vision loss**: In advanced stages, the central vision may be affected, potentially leading to blindness.
- **White patches on the retina**: Observable during an eye examination.

The progression and severity of symptoms can vary, but the condition generally worsens with age.
Prognosis: Choroideremia is a rare, X-linked recessive disorder characterized by progressive vision loss due to degeneration of the choroid, retinal pigment epithelium, and retina. The prognosis varies among individuals but generally involves a gradual decline in vision, leading to eventual blindness typically by middle age. The rate of progression can differ, and early symptoms often include difficulty seeing in low light and peripheral vision loss. There is currently no cure, but research into potential treatments, including gene therapy, is ongoing.
Onset: Choroideremia typically has an onset in childhood, often with night blindness being one of the first symptoms. As the condition progresses, patients experience peripheral vision loss, which gradually leads to tunnel vision and, eventually, significant vision impairment or blindness later in life.
Prevalence: Choroideremia is a rare genetic disorder. The prevalence is estimated to be approximately 1 in 50,000 to 100,000 males. It primarily affects males due to its X-linked recessive inheritance pattern.
Epidemiology: Choroideremia is a rare, X-linked recessive disorder primarily affecting males. The estimated prevalence is about 1 in 50,000 to 1 in 100,000 individuals. It leads to progressive vision loss due to degeneration of the choroid, retinal pigment epithelium, and photoreceptors in the eye. Females can be carriers and may exhibit milder symptoms but generally do not experience the same degree of vision impairment as males.
Intractability: Choroideremia is currently considered intractable, meaning that there is no definitive cure for the condition. It is a rare, genetic disorder that leads to progressive vision loss due to the degeneration of the choroid, retinal pigment epithelium, and photoreceptors in the eye. Research is ongoing, and gene therapy has shown promise in clinical trials, but as of now, there is no widely available treatment to halt or reverse the progression of the disease.
Disease Severity: Choroideremia is a progressive, X-linked recessive retinal disorder that primarily affects males. The disease severity varies among individuals but generally leads to significant vision loss over time. Early symptoms often include difficulty seeing at night (night blindness) and a progressive narrowing of the field of vision (tunnel vision). Eventually, individuals with choroideremia may lose their central vision as well, although the rate of progression can differ.
Healthcare Professionals: Disease Ontology ID - DOID:9821
Pathophysiology: Choroideremia is a rare, X-linked recessive disorder characterized by progressive degeneration of the choroid, retinal pigment epithelium (RPE), and photoreceptors. It is caused by mutations in the CHM gene, which encodes Rab escort protein 1 (REP-1). The absence or malfunction of REP-1 leads to defective intracellular trafficking of Rab proteins, essential for membrane transport and cellular homeostasis. This, in turn, results in the progressive loss of retinal cells and vision impairment, typically manifesting as night blindness in childhood and peripheral vision loss that can advance to complete blindness in adulthood.
Carrier Status: Carrier Status:
- Choroideremia is an X-linked recessive disorder.
- Females are typically the carriers, as they have two X chromosomes. A female carrier has one mutated CHM gene on one X chromosome and a normal CHM gene on the other.
- Male carriers do not exist for X-linked recessive disorders like choroideremia because males have only one X chromosome. If a male inherits the mutated CHM gene, he will manifest the disease.

Nan:
- It seems there may be a typo or misunderstanding here. If you meant "not applicable," please clarify the specific context or concept you are referencing regarding "nan." If it pertains to something specific in genetic terminology, please provide additional details.
Mechanism: Choroideremia is an X-linked recessive genetic disorder that primarily affects males and leads to progressive vision loss. The condition is caused by mutations in the CHM gene, which encodes the Rab Escort Protein-1 (REP-1).

**Mechanism:**
The CHM gene mutation impairs the production or function of REP-1, a protein essential for the prenylation of Rab proteins. Rab proteins are a family of small GTPases that regulate intracellular vesicle trafficking. Without functional REP-1, Rab proteins cannot associate correctly with cell membranes, disrupting vesicular transport processes essential for cell function and survival.

**Molecular Mechanisms:**
1. **Gene Mutation**: Mutations in the CHM gene lead to a deficiency or dysfunction of REP-1.
2. **Prenylation Deficit**: REP-1 is involved in the post-translational modification of Rab GTPases, specifically their prenylation, which is essential for their attachment to cell membranes.
3. **Cellular Disruption**: The lack of prenylated Rab proteins disrupts intracellular vesicle transport, affecting processes like endocytosis, exocytosis, and lysosomal function.
4. **Retinal Degeneration**: The retinal pigment epithelium (RPE) and photoreceptors are particularly sensitive to disruptions in vesicle trafficking. The impaired function of these cells leads to their degeneration, causing progressive vision loss that characterizes choroideremia.

Understanding these molecular mechanisms provides insights into potential therapeutic approaches, such as gene therapy to replace the defective CHM gene, aiming to restore REP-1 function.
Treatment: Choroideremia is a rare, inherited disorder that causes progressive vision loss due to degeneration of the choroid, retina, and retinal pigment epithelium. Currently, there is no cure for choroideremia. However, gene therapy is a promising area of research aimed at slowing or stopping the progression of the disease. The experimental gene therapy treatment involves injecting a functional copy of the CHM gene into the retina to compensate for the defective gene. This approach has shown some success in clinical trials, but it is not yet widely available as a standard treatment. Other supportive measures include regular monitoring by an eye specialist, low vision aids, and adaptive strategies to help manage vision loss.
Compassionate Use Treatment: Choroideremia is a rare, inherited retinal disorder that leads to progressive vision loss. Treatment options under compassionate use or experimental treatments for choroideremia include:

1. **Gene Therapy (e.g., AAV2-REP1)**: One of the most investigated approaches involves using adeno-associated virus (AAV) vectors to deliver the REP1 gene directly into retinal cells. Clinical trials have shown promising results in slowing or halting the progression of vision loss.

2. **CRISPR/Cas9 Gene Editing**: This experimental technique involves editing the patient's DNA to correct the mutation causing choroideremia. Research is still in early stages, but it holds potential for future treatments.

3. **Retinal Implants**: Devices like the Argus II Retinal Prosthesis System have been used experimentally to restore some degree of vision in individuals with severe visual impairment, though primarily in other conditions like retinitis pigmentosa.

4. **Neuroprotective Agents**: Experimental use of agents intended to protect retinal cells from degeneration, such as antioxidants or growth factors, is being investigated in laboratory settings and early-phase clinical trials.

5. **Stem Cell Therapy**: This involves using stem cells to replace or repair damaged retinal cells. While still experimental, some studies are exploring the efficacy and safety of this approach.

Patients interested in these options should consult with their healthcare providers and consider enrolling in clinical trials to access the latest experimental treatments.
Lifestyle Recommendations: For individuals with choroideremia, a rare genetic disorder that causes progressive vision loss, lifestyle recommendations include:

1. **Regular Eye Exams**: Routine check-ups with an ophthalmologist to monitor disease progression.
2. **Genetic Counseling**: For family planning and understanding the inheritance pattern.
3. **Adaptive Aids**: Using visual aids such as magnifiers, screen readers, and proper lighting to cope with vision impairment.
4. **Protective Eyewear**: Wearing sunglasses to protect eyes from UV light.
5. **Safety Measures**: Ensuring home and work environments are safe to prevent falls and injuries.
6. **Physical Activity**: Maintaining overall health through regular exercise, which can help improve quality of life.
7. **Support Groups**: Joining support groups for emotional support and information sharing.

Consulting healthcare professionals for personalized recommendations is crucial.
Medication: Choroideremia is a rare, X-linked genetic condition primarily affecting males. It leads to progressive vision loss due to the degeneration of the choroid, retinal pigment epithelium, and photoreceptors in the eye. Currently, there are no medications approved specifically for treating choroideremia. Research is ongoing, and gene therapy has shown promise in clinical trials as a potential treatment to slow or halt the progression of the disease. Patients are advised to have regular check-ups with an eye care professional to monitor their condition and discuss emerging treatment options.
Repurposable Drugs: Choroideremia is a rare genetic disorder that leads to progressive vision loss, primarily affecting males. Currently, there are no widely accepted repurposable drugs specifically for choroideremia. However, gene therapy, particularly with the use of adeno-associated virus (AAV) vectors, has shown promise in clinical trials. Research into repurposable drugs is ongoing, but as of now, there are no validated medications available.
Metabolites: Choroideremia is an X-linked recessive disorder that primarily affects the choroid, retinal pigment epithelium, and photoreceptors in the eye, leading to progressive vision loss. It is caused by mutations in the CHM gene, which encodes for Rab escort protein-1 (REP-1).

As for metabolites, research is ongoing to fully understand the metabolic changes associated with choroideremia. Some studies have indicated alterations in lipid metabolism and disruptions in oxidative phosphorylation due to the impaired function of REP-1, although specific metabolites directly implicated in choroideremia are not well-documented yet. Further research is needed to elucidate the complete metabolomic profile linked to this condition.
Nutraceuticals: Choroideremia is a rare, inherited disorder that causes progressive vision loss, primarily affecting males. As of my knowledge cutoff, there are no nutraceuticals specifically proven to treat choroideremia. Research is ongoing to understand the disease better and develop effective treatments. Always consult with a healthcare professional for personalized advice.
Peptides: For choroideremia, which is a rare inherited disorder that leads to progressive vision loss due to degeneration of the choroid, retina, and retinal pigment epithelium, peptide therapies are currently under research but not widely established. Certain peptide-based approaches are explored as potential treatments for genetic retinal diseases, but for choroideremia, gene therapy (such as using AAV vectors to deliver functional CHM gene) is more advanced and showing promising clinical trial results. Nanotechnology could potentially be utilized to improve delivery systems for treatments, but this is also still largely experimental.